Mon.Apr 04, 2022

article thumbnail

NIH funds study to evaluate long-term COVID in children

pharmaphorum

The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it’s scientifically known, post-acute sequelae of SARS-CoV-2 (PASC) in children. An estimated 10% to 30% of adults who contract COVID-19 suffer from long COVID. Though speciality departments and independent institutions have opened to study chronic COVID in adults, little research has been done to evaluate the long-term effects of the virus on children.

Vaccines 111
article thumbnail

Takeaways From The American Academy of Dermatology’s Annual Conference

Pharma Marketing Network

The American Academy of Dermatology (AAD) held its annual conference last weekend, and it was my privilege to be in attendance. As COVID-19 had put the brakes on the show for the past two years, that same sentiment was shared by most of the attendees and exhibitors this year. Admittedly, attendance was down slightly from previous years, but that just meant shorter lines and extra opportunity to learn at each booth, and I have no doubt that it will exceed its former glory once COVID goes the way

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

pharmaphorum

Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway. The US regulator has cleared Kite’s CD19-targeted CAR-T Yescarta (axicabtagene ciloleucel) for people with large B-cell lymphoma (LBCL) refractory to one earlier therapy, or who have relapsed within 12 moths of first-line chemo-immunotherapy.

FDA 69
article thumbnail

Digital Medicine Society launches digital endpoint toolkit

Outsourcing Pharma

Working with numerous partners, DiMe has introduced the 3Ps of Digital Endpoint Value to help inclusion of digital endpoints in drug reimbursement decisions.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pharma-backed antibiotic fund makes first investments

pharmaphorum

Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – started life with $1 billion earmarked to support companies trying to develop antibiotics that can be used to replace those that have star

article thumbnail

AbbVie and We Are Pioneer Group link to accelerate life-changing innovations

Pharma Times

Golden Ticket programme is open to early-stage life sciences companies and biotech start-ups which are focusing on cutting edge therapies

48

More Trending

article thumbnail

UK government awards Croda International ÂŁ15.9m grant for manufacturing facility

Pharma Times

Investments will enhance the development of lipid systems manufacturing, while also boosting the development of gene therapies

49
article thumbnail

AXA beefs up life sciences investments with $500m push

pharmaphorum

Multinational insurance company AXA has launched a new €440 million ($500 million) drive to provide private equity investments in healthcare companies that deepens its interest in the life sciences sector. Until now, AXA Investment Managers has been focused more on the delivery end of health care – health centres and private hospitals, for example – but the new strategy is directed at four key areas, including biopharma, vaccines, medical devices and diagnostics companies.

article thumbnail

Study uncovers new Alzheimer’s genes, links to immune disruption

pharmaphorum

The largest-ever study of genetics in Alzheimer’s disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder. The new genes takes the total number associated with Alzheimer’s to 75, opening up new avenues for research of ways to diagnose and treat the conditions, and suggest that immunological dysfunction may have a greater role to play than previously thought.

article thumbnail

CMO John Tsai exits, as Novartis starts revamp that aims to save $1bn

pharmaphorum

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major changes to its organisational structure, including the merger of its pharmaceuticals and oncology businesses into a single unit known as innovative medicines (IM) with separate US and international commercial operations, according to this morning’s announcement.

59
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.